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Between February and April 2018, three ceftriax-
one-resistant and high-level azithromycin-resist-
ant Neisseria gonorrhoeae cases were identified; one 
in the United Kingdom and two in Australia. Whole 
genome sequencing was used to show that the iso-
lates from these cases belong to a single gonococcal 
clone, which we name the A2543 clone.
Between February and April 2018,  Neisseria gon-
orrhoeae  (NG) isolates displaying ceftriaxone 
resistance and high-level azithromycin resistance were 
independently reported from both the United Kingdom 
(UK) (one case) and Australia (two cases) [1,2]. Here, 
genomic analysis is used to demonstrate that these 
cases were caused by a single clone of extensively 
drug-resistant (XDR) NG. This study has demonstrated 
that a single XDR clone, with epidemiological links to 
Asia, has been successfully transmitted on least three 
independent occasions and may be still circulating, 
which is of global public health significance.
Case description
Of three XDR NG cases, the first was identified in 
February 2018, in a heterosexual male in the UK, pre-
senting with urethral discharge, who reported sexual 
contact with a female resident in Thailand in January 
2018 [1]. NG was cultured from both a urethral swab 
taken at the first clinical presentation (G97687) and a 
pharyngeal swab taken during follow-up (G7944). The 
two Australian cases were identified in March and April 
2018. One case was a male experiencing urethral dis-
charge, who reported sexual contact with a female in 
south-east Asia, the other case was female, who pre-
sented with cervicitis, with no travel history outside of 
Australia [2].
Extensive drug resistance
First line treatment for NG typically involves a dual treat-
ment regime of ceftriaxone (500mg intramuscularly) 
and azithromycin (1 or 2g orally). While in the past 10 
years, there have been numerous reports of sustained 
transmission of high-level azithromycin resistant NG, 
there has only been several different gonococcal strains 
observed exhibiting ceftriaxone resistance and these 
have been sporadic (i.e. limited or no further reports of 
transmission). Prior to the three cases reported here, 
no ceftriaxone resistant isolates have additionally 
exhibited high-level resistance to azithromycin (mini-
mum inhibitory concentration (MIC) ≥ 256 mg/L) [3-8]. 
Isolates from the three cases exhibited both resistance 
to ceftriaxone (0.25–0.5 mg/L) and high-level resist-
ance to azithromycin according to European Committee 
on Antimicrobial Susceptibility Testing (EUCAST) resist-
ance breakpoints, requiring the patients to undergo 
extensive follow-up and treatments including days 
of hospitalisation and intravenous therapies [1,2]. All 
2 www.eurosurveillance.org
three patients were subsequently followed up for test 
of cure and confirmed to have cleared their infection.
Genomic analysis
The pharyngeal isolate from the UK case has been 
recently assigned as the World Health Organization 
(WHO) reference strain Q (WHO-Q; NCTC 14208), while 
the two isolates from the Australian cases represent 
a cluster referred to as the A2543 clone [1,2]. Isolates 
from each of the three cases were independently whole 
genome sequenced in the UK and Australia (European 
Nucleotide Archive (ENA) PRJEB26560 for UK ure-
thral (G97687) and pharyngeal (G7944) isolates, and 
PRJEB29480 for Australian male (A2735) and female 
(A2543) case isolates). All four isolates shared the 
same NG-multi-antigen sequence type (NG-MAST) (ST 
16848), multilocus sequence type (MLST) (ST 12039) 
and NG-Sequence Typing for Antimicrobial Resistance 
type (NG-STAR 996) [5]. The isolates harboured a 
mosaic penA allele, type 60.001, conferring ceftriaxone 
resistance as well as four copies of the 23S rRNA 
A2059G mutation responsible for high-level azithro-
mycin resistance [9,10]. These findings suggest the UK 
and Australian isolates are all closely related, however 
the exact phylogenetic relationship between them has 
not yet been determined.
Phylogenetic investigation
We mapped UK and Australian sequence reads against 
a hybrid assembly reference generated from one of 
the UK isolates, G97687, and compared the sequences 
as described previously [1]. The  Figure  shows a 
Figure 
Phylogeny of United Kingdom and Australian sequences obtained in February–April 2018 and the most closely related 
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SNPs: single nucleotide polymorphisms; UK: United Kingdom.
The figure shows a recombination-corrected maximum likelihood phylogeny (drawn using PhyML [14] and ClonalFrameML [15] as described in 
[12]) based on mapping to a novel hybrid assembly of one of the UK isolates (G97687). Branch lengths are labelled in SNPs.
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recombination-corrected maximum likelihood 
phylogeny of the four sequences from the three XDR 
NG cases and the six most closely related publicly 
available sequences in the ENA and National Center for 
Biotechnology Information (NCBI) short read archives. 
Sequences from the two isolates from the UK case and 
the isolate from female Australian case were indistin-
guishable; there was only one single nucleotide poly-
morphism (SNP) between these three isolates and the 
male Australian case. 
The most closely related comparison sequences from 
the short read archive were all high-level azithro-
mycin resistant, but lacked the  penA  allele seen in 
the UK and Australian cases [11]. These comparison 
sequences were >  60 SNPs different, consistent with 
having a common ancestor several years earlier, based 
on estimated rates of evolution for NG of around 3.6 
SNPs per genome per year [12]. No more closely related 
sequences are currently available.
Discussion
The first three ceftriaxone-resistant, high-level azithro-
mycin resistant NG isolates seen worldwide were 
isolated within a two-month period of each other 
(February–April 2018). The mechanisms of resistance, 
including the penA60.001 allele associated with ceftri-
axone resistance, and molecular genotypes have been 
reported elsewhere [1,2], however a detailed phylo-
genetic analysis between the isolates remained to be 
performed. In this study, we have demonstrated that 
isolates from the three cases are tightly genetically 
clustered and distinct from other globally distributed 
publicly available NG sequences. The limited SNP dif-
ferences between the XDR isolates provides compel-
ling evidence that the UK and Australian NG cases are 
highly related and of the same gonococcal clone. The 
isolation of these A2543 clone XDR gonococci within a 
short time period, with epidemiological links to south-
east Asia in two of three cases, suggests that this 
clone may be circulating in Asia, which is concerning. It 
is important to note that the both the UK and Australia 
have active NG antimicrobial resistance (AMR) sur-
veillance programs, which were instrumental to the 
culture, detection and appropriate follow up of these 
cases. Further, while these cases likely only represent 
sporadic importations into the UK and Australia, it is 
highly probable that the clone is present elsewhere, 
but may not have been detected due to lack of testing 
and surveillance.
Further spread of this A2543 XDR strain would have 
serious implications for the current first-line NG treat-
ment recommendations. The multiple detections of the 
A2543 clone, including asymptomatically in the phar-
ynx in one case highlights the need to improve culture-
based NG AMR surveillance in many regions, as well as 
ensuring clinicians collect pharyngeal samples – a site 
important from both transmission and treatment clear-
ance perspectives. We have described a PCR that can 
detect the penA 60.001 allele associated with both the 
A2543 clone and FC428 strains [13] and which could be 
used for direct molecular screening to further enhance 
surveillance activities. International collaboration is 
key to assisting in the prevention and control of what 
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